328 related articles for article (PubMed ID: 27904651)
21. Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy.
Grande E; Alonso-Gordoa T; Reig O; Esteban E; Castellano D; Garcia-Del-Muro X; Mendez MJ; García-Donas J; González Rodríguez M; Arranz-Arija JA; Lopez-Criado P; Molina-Cerrillo J; Mellado B; Alvarez-Fernandez C; De Velasco G; Cuéllar-Rivas MA; Rodríguez-Alonso RM; Rodríguez-Moreno JF; Suarez-Rodriguez C
ESMO Open; 2022 Apr; 7(2):100463. PubMed ID: 35405437
[TBL] [Abstract][Full Text] [Related]
22. Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.
Ansari J; Fatima A; Fernando K; Collins S; James ND; Porfiri E
Oncol Rep; 2010 Aug; 24(2):507-10. PubMed ID: 20596640
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J
Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503
[TBL] [Abstract][Full Text] [Related]
24. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma.
Guida FM; Santoni M; Conti A; Burattini L; Savini A; Zeppola T; Caricato M; Cascinu S; Tonini G; Santini D
Crit Rev Oncol Hematol; 2014 Dec; 92(3):208-17. PubMed ID: 25151214
[TBL] [Abstract][Full Text] [Related]
25. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST).
Le Tourneau C; Raymond E; Faivre S
Ther Clin Risk Manag; 2007 Jun; 3(2):341-8. PubMed ID: 18360643
[TBL] [Abstract][Full Text] [Related]
26. [Alternative prescription schedules of sunitinib in metastatic kidney cancer: from the underground to the light?].
Thiery-Vuillemin A; Mouillet G; Pouessel D; Barthelemy P; Caty A; Sebbagh S; Vanno YA; Laplaige P; Cheverau C; Ravaud A
Bull Cancer; 2014 Sep; 101(9):832-40. PubMed ID: 25295955
[TBL] [Abstract][Full Text] [Related]
27. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
Markham A
Target Oncol; 2022 Mar; 17(2):193-201. PubMed ID: 35175500
[TBL] [Abstract][Full Text] [Related]
28. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
29. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
[TBL] [Abstract][Full Text] [Related]
30. The prospects of pazopanib in advanced renal cell carcinoma.
Gupta S; Spiess PE
Ther Adv Urol; 2013 Oct; 5(5):223-32. PubMed ID: 24082917
[TBL] [Abstract][Full Text] [Related]
31. Pazopanib: a Review in Advanced Renal Cell Carcinoma.
Frampton JE
Target Oncol; 2017 Aug; 12(4):543-554. PubMed ID: 28664385
[TBL] [Abstract][Full Text] [Related]
32. Experience with sunitinib in the treatment of metastatic renal cell carcinoma.
Schmidinger M; Larkin J; Ravaud A
Ther Adv Urol; 2012 Oct; 4(5):253-65. PubMed ID: 23024706
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
Gore ME; Szczylik C; Porta C; Bracarda S; Bjarnason GA; Oudard S; Hariharan S; Lee SH; Haanen J; Castellano D; Vrdoljak E; Schöffski P; Mainwaring P; Nieto A; Yuan J; Bukowski R
Lancet Oncol; 2009 Aug; 10(8):757-63. PubMed ID: 19615940
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era.
Numakura K; Muto Y; Naito S; Hatakeyama S; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Obara W; Ohyama C; Tsuchiya N; Habuchi T
Cancer Med; 2021 Sep; 10(17):5839-5846. PubMed ID: 34313025
[TBL] [Abstract][Full Text] [Related]
35. Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.
Haaland B; Chopra A; Acharyya S; Fay AP; Lopes Gde L
BMC Cancer; 2014 Aug; 14():592. PubMed ID: 25127891
[TBL] [Abstract][Full Text] [Related]
36. Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma.
Tegos T; Tegos K; Dimitriadou A; Dimitriadis G
J BUON; 2019; 24(4):1340-1353. PubMed ID: 31646776
[TBL] [Abstract][Full Text] [Related]
37. Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting.
Nikic P; Babovic N; Dzamic Z; Salma S; Stojanovic V; Matkovic S; Pejcic Z; Juskic K; Soldatovic I
Front Oncol; 2022; 12():892156. PubMed ID: 35756652
[TBL] [Abstract][Full Text] [Related]
38. Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States.
Hackshaw MD; Holmes M; Lankford M; Thomas M; Ogbonnaya A; Eaddy M
Clin Genitourin Cancer; 2016 Oct; 14(5):e479-e487. PubMed ID: 27221141
[TBL] [Abstract][Full Text] [Related]
39. Assessment of Sunitinib Alternative Prescription Schedules in Metastatic Kidney Cancer: A Study of 10 Cases.
Diallo H; Mhamdi HA; Elouarzazi S; Fadli M; Belbaraka R
Gulf J Oncolog; 2018 Jan; 1(26):33-36. PubMed ID: 29607820
[TBL] [Abstract][Full Text] [Related]
40. An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.
Powles T; Sarwar N; Jones R; Wilson P; Boleti E; Protheroe A; Crabb SJ; Shamash J; Stockdale A; Rashid S; Nathan P; Chowdury S
Eur J Cancer; 2012 Nov; 48(17):3171-6. PubMed ID: 22766517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
